Core Insights - Apyx Medical Corporation is set to participate in two upcoming investor conferences, showcasing its proprietary technologies [1][2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as Renuvion and the AYON Body Contouring System™ [3] - Renuvion and J-Plasma technologies provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical documents [3] - The AYON Body Contouring System™ is an FDA-cleared platform that integrates multiple capabilities for comprehensive body contouring treatments [3] - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

~ Continued strong sales and profit growth in 3Q25 ~~ Updating 2025 sales and profit outlook; providing preliminary outlooks for 2026 and 2027 ~ PLANO, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended September 26, 2025. Third Quarter 2025 Highlights (compared to Third Quarter 2024, except as noted) Sales increased 8% to $468 million, with organic growth of 7%.GAAP operating income decreased $2 million to $56 million, a decr ...

Core Viewpoint - Boston Scientific Corporation is positioned for growth with expected increases in earnings and revenue, despite a slight downward revision in EPS estimates [2][3][6] Financial Performance - The company is projected to report an earnings per share (EPS) of $0.71, reflecting a 12.7% increase year-over-year [2][6] - Revenue is anticipated to reach approximately $4.97 billion, marking an 18% rise compared to the same period last year [2][6] - Boston Scientific has a history of exceeding earnings expectations, with an average surprise of 8.11% over the past four quarters [4] Market Position and Innovations - The company specializes in a wide range of medical devices for interventional specialties, with key innovations like the WATCHMAN FLX Pro and AGENT DCB enhancing its market position [1] Financial Metrics - The company has a price-to-earnings (P/E) ratio of approximately 59.41, indicating a high valuation relative to earnings [5][6] - A debt-to-equity ratio of 0.54 suggests a moderate level of debt relative to equity [5][6] - The current ratio of about 1.37 indicates reasonable liquidity to cover short-term liabilities [5]

Investment Commitment - A prominent institutional investment fund has committed to providing up to $5,000,000 in financing to American Diversified Holdings Corporation (ADHC) [1][2] Use of Funds - The investment proceeds are designated for the research and development of the GlucoGuard project and for general corporate purposes, as well as to support collaboration with DexCom, a Continuous Glucose Monitoring (CGM) development partner [2] FDA Interaction - ADHC has engaged with its Medical Advisory Board and the FDA, leading to a request for a two-prong sleep study to address safety and efficacy concerns regarding the GlucoGuard device [3] FDA Review - The major components of the Breakthrough Device Application Designation have received positive feedback from the FDA regarding the unmet need and GlucoGuard's potential to assist patients [4] Company Mission - The investment is expected to enhance ADHC's valuation and support its mission to help Type 1 Diabetics manage hypoglycemic events, thereby improving patients' lives [5]

Core Insights - The article highlights a groundbreaking clinical case study demonstrating the successful use of a 308-nm excimer laser in treating poikilodermatous mycosis fungoides (pMF), a rare subtype of cutaneous T-cell lymphoma [1][2][8] Company Overview - STRATA Skin Sciences, Inc. is a medical technology company focused on developing and marketing innovative products for dermatologic conditions, including the XTRAC excimer laser [1][12] - The company is actively working with the Centers for Medicare and Medicaid Services (CMS) to expand reimbursement codes for a wider range of conditions treated by the XTRAC laser [3] Clinical Study Details - The study, led by dermatology researchers at Tohoku University, is the first English-language report validating excimer laser therapy as a safe and effective treatment for pMF [2][3] - The case study involved a 50-year-old female patient with a 3-year history of progressive lesions, who showed marked improvement after treatment with the excimer laser [6][7] Treatment Efficacy - A systematic review published in 2022 indicated that 73.6% of patients with mycosis fungoides achieved a complete clinical response using the 308-nm excimer laser, with a low relapse rate of 5.7% [4] - The excimer laser offers a targeted treatment option that minimizes exposure to unaffected skin, contrasting with traditional therapies that require whole-body exposure [9][10] Market Implications - The successful application of the excimer laser in treating pMF could influence future treatment guidelines and improve patient quality of life in this rare disease population [11] - Japan is identified as a significant market for the XTRAC excimer laser, with local dermatologists pioneering new uses for the technology [3]

Market Overview - The S&P 500 dropped 0.28% to 6,735.11, the Nasdaq slipped 0.08% to 23,024.63, and the Dow fell 243.36 points, or 0.52%, closing at 46,358.42 due to concerns over the ongoing U.S. government shutdown [1] - Investors are closely monitoring the potential impacts of the shutdown on economic activity and corporate results, leading to a cautious market sentiment [1] Value Investing Insights - The Price to Cash Flow (P/CF) ratio is highlighted as an effective valuation metric for assessing value stocks, with a lower P/CF indicating better value and strong cash generation potential [2][3] - Analysts emphasize that cash flow is a more reliable indicator of a company's financial health compared to earnings, which can be subject to manipulation [4] Selection Criteria for Value Stocks - Parameters for selecting true-value stocks include: - P/CF less than or equal to the industry median - Price greater than or equal to $5 - Average 20-Day Volume greater than 100,000 - P/E using (F1) less than or equal to the industry median [7][8] - Additional metrics include P/B, P/S, PEG ratios, and Zacks Rank to avoid value traps and identify stocks with strong upside potential [6][10] Featured Value Stocks - StoneCo Ltd. (STNE) has a trailing four-quarter earnings surprise of 11.5% and a Value Score of B, with expected sales and EPS growth of 9.8% and 20% respectively [12][11] - Integer Holdings Corporation (ITGR) has a trailing four-quarter earnings surprise of 1.3% and a Value Score of B, with expected sales and EPS growth of 7.8% and 20.4% respectively [13][12] - Universal Health Services, Inc. (UHS) has a trailing four-quarter earnings surprise of 9.4% and a Value Score of A, with expected sales and EPS growth of 8.5% and 23% respectively [15][14] - Great Lakes Dredge & Dock Corporation (GLDD) has a trailing four-quarter earnings surprise of 45.3% and a Value Score of A, with expected sales and EPS growth of 9% and 21.4% respectively [16][15]

Core Insights - Neogen Corporation (NEOG) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of 4 cents, missing the Zacks Consensus Estimate by 20% and reflecting a 42.9% decline from the previous year [1][10] - Revenues for the quarter decreased 3.6% year-over-year to $209.2 million, with core revenues increasing by 0.3% [2][10] - Following the earnings announcement, NEOG stock rose by 16.5% to close at $6.78 [2] Revenue Breakdown - The Food Safety segment generated revenues of $152.1 million, a 4.6% decrease year-over-year, with a core revenue decline of 1.7% [3][4] - The Animal Safety segment reported revenues of $57.1 million, down 0.8% year-over-year, but core revenues increased by 5.8% [5] - The Genomics business returned to positive core revenue growth in the mid-single-digit range [6] Margin and Expense Analysis - Gross profit declined 9.5% year-over-year to $95 million, with gross margin contracting by 296 basis points to 45.4% [7] - Sales and marketing expenses were $45 million, down 1.6% year-over-year, while administrative expenses increased by 17.8% to $61 million [8] Cash Position and Liabilities - Neogen's cash and cash equivalents at the end of the first quarter totaled $138.9 million, up from $129 million at the end of the previous quarter [9] - The company has total outstanding debt of $800 million and a committed borrowing headroom of $201.5 million [9] Fiscal 2026 Outlook - Neogen reaffirmed its fiscal 2026 revenue projections of $820-$840 million, with adjusted EBITDA expected to be between $165 million and $175 million [11][10] - Capital expenditures are projected to be around $50 million [11] Performance Summary - The company ended the first quarter with mixed results, as earnings missed expectations while revenues exceeded estimates [12] - Execution challenges have impacted performance, but the company is focusing on commercial excellence and cost structure improvements [12][13]

Core Insights - PAVmed Inc. and its subsidiary Veris Health have entered the commercial phase of their partnership with The Ohio State University Comprehensive Cancer Center to enhance personalized cancer care through the Veris Cancer Care Platform [1][2] Company Overview - PAVmed Inc. is a diversified commercial-stage medical technology company operating in medical devices, diagnostics, and digital health sectors [5] - Veris Health, a majority-owned subsidiary of PAVmed, focuses on digital health and has developed a digital cancer care platform aimed at improving personalized cancer care through remote patient monitoring [5] Partnership Details - The partnership with OSUCCC – James aims to expand the clinical deployment of the Veris platform, which includes launching a clinical registry for patients enrolled in the program [2] - The Veris Cancer Care Platform features remote physiological data collection, symptom reporting, telehealth capabilities, and electronic health record integration [2][3] Platform Features - Patients enrolled in the Veris platform receive a VerisBox™ containing connected health care devices that transmit physiological data to a cloud-based clinician portal [3] - A patient portal allows symptom reporting and health tracking via a smartphone app, which also enables family members to participate in the patient's care journey [3] Future Developments - Veris is developing an implantable physiological monitor to be used alongside a vascular access port, enhancing the platform's clinical and commercial value by providing remote data independent of patient compliance [3]

Core Insights - Polyrizon Ltd. announced positive results from a pre-clinical study of its PL-14 Allergy Blocker formulation, demonstrating its effectiveness in blocking allergens, specifically the Der p 1 allergen from house dust mites [1][2][5] Company Overview - Polyrizon is a biotechnology company focused on developing intranasal products using its proprietary Capture & Contain (C&C) platform, which creates a hydrogel barrier to protect against allergens and viruses [6] Study Results - The pre-clinical study showed that PL-14 significantly limited allergen diffusion, with only 1.07% of the allergen penetrating after one hour, 1.14% after two hours, and 13.6% after four hours [8] - The allergen load used in the study was significantly higher than typical exposure levels, suggesting that PL-14 may provide strong protection even in extreme conditions [3] Market Potential - The Allergy Immunotherapy market is projected to grow from USD 1.9 billion in 2025 to USD 4.2 billion by 2035, with a CAGR of 7.9%, driven by the rising prevalence of allergies and advancements in treatment methodologies [4] Future Plans - Polyrizon plans to advance its preclinical development program and initiate clinical studies to support regulatory pathways for PL-14 and other candidates within the C&C platform [5][9]

Core Insights - The Beauty Health Company has appointed Pedro Malha as the new President and CEO, effective October 1, 2025, succeeding Marla Beck, who will transition to an advisory role [1][2][3] Leadership Transition - Pedro Malha brings over 20 years of experience in the healthcare and medical device sectors, having previously served as Worldwide Division President at Abbott Laboratories [3][4] - Marla Beck is credited with guiding the company through significant transformation, enhancing the innovation pipeline, and improving operational efficiency during her tenure [2][3] Company Strategy and Vision - The company aims to leverage its robust pipeline of innovation and brand initiatives to drive growth under Malha's leadership [3] - Malha emphasizes the potential of the Hydrafacial brand at the intersection of beauty and health, focusing on science-backed innovation and operational excellence [4] Company Overview - The Beauty Health Company (NASDAQ: SKIN) specializes in skin health experiences, with flagship brands including Hydrafacial, SkinStylus, and Keravive, catering to diverse consumer needs [5]